JP2019519528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519528A5 JP2019519528A5 JP2018561641A JP2018561641A JP2019519528A5 JP 2019519528 A5 JP2019519528 A5 JP 2019519528A5 JP 2018561641 A JP2018561641 A JP 2018561641A JP 2018561641 A JP2018561641 A JP 2018561641A JP 2019519528 A5 JP2019519528 A5 JP 2019519528A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- domain monomer
- domain
- sequence
- construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 126
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 126
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 126
- 239000000178 monomer Substances 0.000 claims description 66
- 239000006143 cell culture medium Substances 0.000 claims description 13
- 230000035772 mutation Effects 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 150000001413 amino acids Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 150000002333 glycines Chemical class 0.000 claims description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000005931 immune cell recruitment Effects 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022044109A JP7295301B2 (ja) | 2016-05-23 | 2022-03-18 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340322P | 2016-05-23 | 2016-05-23 | |
| US62/340,322 | 2016-05-23 | ||
| US201762443451P | 2017-01-06 | 2017-01-06 | |
| US62/443,451 | 2017-01-06 | ||
| PCT/US2017/034084 WO2017205434A1 (en) | 2016-05-23 | 2017-05-23 | Compositions and methods related to engineered fc constructs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022044109A Division JP7295301B2 (ja) | 2016-05-23 | 2022-03-18 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2019519528A JP2019519528A (ja) | 2019-07-11 |
| JP2019519528A5 true JP2019519528A5 (OSRAM) | 2020-07-02 |
| JP7045333B2 JP7045333B2 (ja) | 2022-03-31 |
| JP7045333B6 JP7045333B6 (ja) | 2022-05-06 |
Family
ID=60412547
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561639A Withdrawn JP2019519527A (ja) | 2016-05-23 | 2017-05-23 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2018561641A Active JP7045333B6 (ja) | 2016-05-23 | 2017-05-23 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2022010912A Pending JP2022068176A (ja) | 2016-05-23 | 2022-01-27 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2022044109A Active JP7295301B2 (ja) | 2016-05-23 | 2022-03-18 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2024193057A Withdrawn JP2025026880A (ja) | 2016-05-23 | 2024-11-01 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561639A Withdrawn JP2019519527A (ja) | 2016-05-23 | 2017-05-23 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022010912A Pending JP2022068176A (ja) | 2016-05-23 | 2022-01-27 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2022044109A Active JP7295301B2 (ja) | 2016-05-23 | 2022-03-18 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2024193057A Withdrawn JP2025026880A (ja) | 2016-05-23 | 2024-11-01 | 操作されたＦｃコンストラクトに関する組成物及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US11623964B2 (OSRAM) |
| EP (2) | EP3464376A4 (OSRAM) |
| JP (5) | JP2019519527A (OSRAM) |
| KR (3) | KR102635635B1 (OSRAM) |
| CN (4) | CN109789203B (OSRAM) |
| AU (2) | AU2017272109B2 (OSRAM) |
| BR (2) | BR112018074032A2 (OSRAM) |
| CA (2) | CA3025310A1 (OSRAM) |
| DK (1) | DK3484514T3 (OSRAM) |
| ES (1) | ES2973251T3 (OSRAM) |
| IL (3) | IL263211B2 (OSRAM) |
| NZ (2) | NZ749279A (OSRAM) |
| PL (1) | PL3484514T3 (OSRAM) |
| SG (3) | SG10202011624SA (OSRAM) |
| WO (2) | WO2017205436A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102546875B1 (ko) | 2014-05-02 | 2023-06-26 | 모멘타 파머슈티컬스 인코포레이티드 | 공학처리된 ｆｃ 작제물과 관련된 조성물 및 방법 |
| EP3423572B1 (en) | 2016-03-02 | 2023-11-29 | Momenta Pharmaceuticals, Inc. | Methods related to engineered fc constructs |
| NZ749279A (en) | 2016-05-23 | 2025-08-29 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
| US11220531B2 (en) * | 2017-01-06 | 2022-01-11 | Janssen Biotech, Inc. | Engineered Fc constructs |
| WO2020014419A2 (en) * | 2018-07-11 | 2020-01-16 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1 |
| BR112021000392A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados |
| EP3820910A4 (en) * | 2018-07-11 | 2022-06-22 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATING TO ENGINEERED FC ANTIGEN-BINDING DOMAIN CONSTRUCTS |
| MX2021000280A (es) * | 2018-07-11 | 2021-11-12 | Momenta Pharmaceuticals Inc | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. |
| WO2020014413A2 (en) * | 2018-07-11 | 2020-01-16 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4 |
| EP3820523A4 (en) * | 2018-07-11 | 2022-03-30 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATING TO ENGINEERED FC ANTIGEN-BINDING DOMAIN CONSTRUCTS |
| US20210269546A1 (en) * | 2018-07-11 | 2021-09-02 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38 |
| CA3105985A1 (en) * | 2018-07-11 | 2020-01-16 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4 |
| KR102661494B1 (ko) | 2019-03-08 | 2024-04-29 | 에이치엘만도 주식회사 | 랙구동형 동력 보조 조향장치 |
| WO2021048330A1 (en) | 2019-09-13 | 2021-03-18 | CSL Behring Lengnau AG | Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders |
| MX2022006703A (es) | 2019-12-06 | 2022-07-12 | CSL Behring Lengnau AG | Composiciones estables de multimeros fc. |
| CN111808170A (zh) * | 2020-06-29 | 2020-10-23 | 江苏为真生物医药技术股份有限公司 | 多肽、hla-dr蛋白及其制备方法和应用 |
| CN117043190A (zh) * | 2020-12-07 | 2023-11-10 | 因外泰克斯公司 | 延长治疗剂在家畜动物中的半衰期的组合物和使用方法 |
| WO2024206820A1 (en) * | 2023-03-30 | 2024-10-03 | Dna Twopointo, Inc. | Fc engineering for heterodimeric antibody format |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2556219B1 (fr) | 1983-12-07 | 1987-06-26 | Merieux Inst | Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines |
| US5426641A (en) | 1994-01-28 | 1995-06-20 | Bell Communications Research, Inc. | Adaptive class AB amplifier for TDMA wireless communications systems |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0975355A2 (en) | 1996-06-14 | 2000-02-02 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
| US20090074839A1 (en) | 1997-01-22 | 2009-03-19 | Marton Milankovits | Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DE60041564D1 (de) | 1999-12-24 | 2009-03-26 | Genentech Inc | Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen |
| US20050089932A1 (en) * | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| TW200833840A (en) | 2006-10-25 | 2008-08-16 | Amgen Inc | Toxin peptide therapeutic agents |
| BRPI0620639A2 (pt) | 2006-12-21 | 2011-11-22 | Micromet Ag | anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos |
| CA2682605A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| KR20100021601A (ko) | 2007-05-14 | 2010-02-25 | 바이오겐 아이덱 엠에이 인코포레이티드 | 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법 |
| KR101580938B1 (ko) | 2007-06-01 | 2015-12-30 | 유니버시티 오브 매릴랜드, 발티모어 | 면역글로불린 불변영역 Ｆｃ 수용체 결합제 |
| WO2010135521A2 (en) | 2009-05-20 | 2010-11-25 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
| AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| PT2247304T (pt) | 2008-04-02 | 2016-08-29 | Macrogenics Inc | Anticorpos especificos de her2/neu e métodos de utilização dos mesmos |
| CA2739581A1 (en) | 2008-10-06 | 2010-04-15 | University Of Chicago | Compositions and methods related to bacterial eap, emp, and/or adsa proteins |
| US20100143353A1 (en) | 2008-12-04 | 2010-06-10 | Mosser David M | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME |
| EP2376105B1 (en) | 2008-12-18 | 2015-07-29 | Dana-Farber Cancer Institute, Inc. | Nkg2d-fc for immunotherapy |
| CA2750533A1 (en) | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
| WO2010135534A2 (en) | 2009-05-20 | 2010-11-25 | Children's Medical Center Corporation | Compositions for the treatment of metastatic cancer and methods of use thereof |
| JP5683581B2 (ja) | 2009-06-30 | 2015-03-11 | リサーチ ディベロップメント ファウンデーション | 免疫グロブリンＦｃポリペプチド |
| MX2012003396A (es) | 2009-09-16 | 2012-04-10 | Genentech Inc | Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos. |
| TR201804897T4 (tr) | 2009-10-07 | 2018-06-21 | Macrogenics Inc | Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler |
| JP2013511281A (ja) | 2009-11-23 | 2013-04-04 | アムジェン インコーポレイテッド | 単量体抗体Ｆｃ |
| GB0922209D0 (en) | 2009-12-18 | 2010-02-03 | Univ Nottingham | Proteins, nucleic acid molecules and compositions |
| US9238080B2 (en) | 2010-05-21 | 2016-01-19 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| DK2591006T3 (da) | 2010-07-09 | 2019-07-29 | Bioverativ Therapeutics Inc | Processerbare enkeltkædede molekyler og polypeptider fremstillet ved anvendelse deraf |
| MX368531B (es) | 2010-07-28 | 2019-10-07 | Gliknik Inc | Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente. |
| AU2011288412A1 (en) | 2010-08-13 | 2013-02-21 | Medimmune Limited | Monomeric polypeptides comprising variant Fc regions and methods of use |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| JP6012624B2 (ja) * | 2010-12-23 | 2016-10-25 | ヤンセン バイオテツク，インコーポレーテツド | 活性プロテアーゼ耐性抗体Ｆｃ突然変異体 |
| WO2012123949A1 (en) | 2011-03-17 | 2012-09-20 | Ramot At Tel-Aviv University Ltd. | Bi- and monospecific, asymmetric antibodies and methods of generating the same |
| US9683052B2 (en) | 2011-03-25 | 2017-06-20 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
| WO2013063702A1 (en) * | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| AU2013270682A1 (en) * | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Procoagulant compounds |
| RU2015101699A (ru) | 2012-06-21 | 2016-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Слитые полипептиды и конъюгаты полипептида лиганда рецептора инкретина и fc-области с измененной fc-эффекторной функцией |
| CN104718223A (zh) * | 2012-08-20 | 2015-06-17 | 格利克尼克股份有限公司 | 具有抗原结合和多价FCγ受体结合活性的分子 |
| US20150218236A1 (en) | 2012-10-17 | 2015-08-06 | Liverpool School Of Tropical Medicine | Immunomodulatory proteins |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| CN104558194B (zh) | 2013-10-17 | 2018-04-27 | 泰州迈博太科药业有限公司 | 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途 |
| US10137170B2 (en) | 2013-12-20 | 2018-11-27 | Indiana University Research And Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides |
| EP3835318B1 (en) | 2014-01-15 | 2025-10-29 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
| EP3094649A1 (en) | 2014-01-15 | 2016-11-23 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn-binding properties |
| TW201619188A (zh) | 2014-03-05 | 2016-06-01 | 優稀美生物醫藥公司 | 多聚體Ｆｃ蛋白質 |
| EP3114137A1 (en) | 2014-03-05 | 2017-01-11 | UCB Biopharma SPRL | Multimeric fc proteins |
| BR112016023948A2 (pt) | 2014-04-16 | 2018-01-30 | Ucb Biopharma Sprl | proteínas fc multiméricas |
| KR102546875B1 (ko) | 2014-05-02 | 2023-06-26 | 모멘타 파머슈티컬스 인코포레이티드 | 공학처리된 ｆｃ 작제물과 관련된 조성물 및 방법 |
| SG10201913324PA (en) | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| EP3423572B1 (en) | 2016-03-02 | 2023-11-29 | Momenta Pharmaceuticals, Inc. | Methods related to engineered fc constructs |
| NZ749279A (en) | 2016-05-23 | 2025-08-29 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
| US11220531B2 (en) | 2017-01-06 | 2022-01-11 | Janssen Biotech, Inc. | Engineered Fc constructs |
-
2017
- 2017-05-23 NZ NZ749279A patent/NZ749279A/en unknown
- 2017-05-23 US US16/303,831 patent/US11623964B2/en active Active
- 2017-05-23 DK DK17803463.3T patent/DK3484514T3/da active
- 2017-05-23 SG SG10202011624SA patent/SG10202011624SA/en unknown
- 2017-05-23 ES ES17803463T patent/ES2973251T3/es active Active
- 2017-05-23 WO PCT/US2017/034087 patent/WO2017205436A1/en not_active Ceased
- 2017-05-23 EP EP17803465.8A patent/EP3464376A4/en active Pending
- 2017-05-23 CN CN201780045710.8A patent/CN109789203B/zh active Active
- 2017-05-23 IL IL263211A patent/IL263211B2/en unknown
- 2017-05-23 AU AU2017272109A patent/AU2017272109B2/en active Active
- 2017-05-23 CA CA3025310A patent/CA3025310A1/en active Pending
- 2017-05-23 JP JP2018561639A patent/JP2019519527A/ja not_active Withdrawn
- 2017-05-23 US US16/303,793 patent/US11155640B2/en active Active
- 2017-05-23 EP EP17803463.3A patent/EP3484514B1/en active Active
- 2017-05-23 BR BR112018074032-2A patent/BR112018074032A2/pt unknown
- 2017-05-23 IL IL309293A patent/IL309293A/en unknown
- 2017-05-23 IL IL263213A patent/IL263213B2/en unknown
- 2017-05-23 AU AU2017272111A patent/AU2017272111B2/en active Active
- 2017-05-23 JP JP2018561641A patent/JP7045333B6/ja active Active
- 2017-05-23 WO PCT/US2017/034084 patent/WO2017205434A1/en not_active Ceased
- 2017-05-23 KR KR1020227037780A patent/KR102635635B1/ko active Active
- 2017-05-23 CN CN201780045688.7A patent/CN109963869A/zh active Pending
- 2017-05-23 KR KR1020187037345A patent/KR102590061B1/ko active Active
- 2017-05-23 CA CA3025306A patent/CA3025306A1/en active Pending
- 2017-05-23 SG SG11201810465RA patent/SG11201810465RA/en unknown
- 2017-05-23 KR KR1020187037334A patent/KR102462084B1/ko active Active
- 2017-05-23 NZ NZ749292A patent/NZ749292A/en unknown
- 2017-05-23 SG SG11201810466PA patent/SG11201810466PA/en unknown
- 2017-05-23 BR BR112018074056-0A patent/BR112018074056A2/pt active Search and Examination
- 2017-05-23 PL PL17803463.3T patent/PL3484514T3/pl unknown
- 2017-05-23 CN CN202210924611.XA patent/CN116063540A/zh active Pending
- 2017-05-23 CN CN202410270902.0A patent/CN118206639A/zh active Pending
-
2021
- 2021-10-01 US US17/491,677 patent/US12297291B2/en active Active
-
2022
- 2022-01-27 JP JP2022010912A patent/JP2022068176A/ja active Pending
- 2022-03-18 JP JP2022044109A patent/JP7295301B2/ja active Active
-
2023
- 2023-04-10 US US18/298,131 patent/US20240067757A1/en active Pending
-
2024
- 2024-11-01 JP JP2024193057A patent/JP2025026880A/ja not_active Withdrawn